InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.55
(
-0.27%
)
Bitcoin
56,411.70
(
-3.24%
)
Post# of 252504
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

xavierprivas

Send PM Follow Ignore
Followers 6
Posts 162
Boards Moderated 0
Alias Born 09/14/2009

xavierprivas

Re: biomaven0 post# 207894

Wednesday, 01/11/2017 3:54:50 PM

Wednesday, January 11, 2017 3:54:50 PM

Post# of 252504
GSK filed on June 30 2016 for inter partes review of FGEN Patent 8,609,646 was denied review by the Patent Office today. Explain why FGEN is up while
most biotechs go down

This is just one patent out the six that Glaxo requested a ipr.
(8,466,172; 8,614,204; 8,629,131; 8,604,012; 8,609,646; and 8,604,013)

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up